$Amphastar Pharmaceuticals (AMPH.US)$🎯 2023.12.6 The curren...

New data: 23Q2 and Q3. Continued significant growth. An acquisition was carried out in Q2, and long-term loans in Q3 increased to 640 million. Interest expenses accounted for 17.2% of operating profit. The burden was not light, and the leverage ratio was also very high.

According to the data for the two quarters, the results of the acquisition were good. Currently, the price-earnings ratio is 33.6, and the price-earnings ratio has dropped to 22.8. If the annual net profit reaches 150 million, the price-earnings ratio will drop to 18.6. There is still a certain discount on the growth rate, but the current high leverage ratio poses new risks, so you can choose carefully (⭐️)